Prospective Evaluation of Focal Brachytherapy Using Cesium-131 For Patients With Low Risk Prostate Cancer

You may be eligible if

• Histologically confirmed adenocarcinoma of the prostate
• Clinical stage T1c-T2aN0M0
• Gleason score \<= 3+3=6
• prostate specific antigen (PSA) \<10 ng/ml
• \<= 2 cores positive out of a minimum of 12 cores sampled